复星医药(600196.SH)：向专业投资者公开发行科技创新公司债券获中国证监会注册批复

Core Viewpoint - Fosun Pharma has received approval from the China Securities Regulatory Commission (CSRC) for the public issuance of technology innovation corporate bonds totaling up to RMB 6 billion [1] Group 1 - The CSRC issued a formal approval document allowing Fosun Pharma to issue corporate bonds aimed at professional investors [1] - The total face value of the bonds that can be issued is capped at RMB 60 billion [1] - The approval is valid for 24 months from the date of issuance, allowing the company to issue the bonds in multiple tranches within this period [1]